Aim To determine population-based incidence of conjunctival tumours in Olmsted County, Minnesota. Methods The Rochester Epidemiology Project medical record linkage system was used to identify patients with conjunctival tumours in Olmsted County (1 January 1980 to 31 December 2015). Records were reviewed for demographics, types of tumours, histopathology, treatment and clinical course. Incidence rate of all tumours was calculated per 1 000 000 person-years. Poisson regression analysis was used to assess changes in incidence over time. results There were 504 patients with conjunctival tumours, giving an age-adjusted and sex-adjusted incidence rate of 125 per 1 000 000 (CI 113.5 to 135.5). Incidence increased over time (P<0.001). Most tumours (474, 94%) were benign. Of benign lesions, melanocytic lesions accounted for the majority (431, 86%), with adjusted incidence rates of 10.8 (CI 7.7 to 13.9) for complexion-associated melanosis, 49.7 (CI 42.9 to 56.6) for nevus and 44.1 (37.5-50.8) for primary acquired melanosis. Malignant lesions were rare (30, 6%) with 6 cases of melanoma, 21 cases of ocular surface squamous neoplasia (OSSN), 1 case of Langerhans cell histiocytosis and 2 cases of lymphoma. Adjusted incidence rates of conjunctival melanoma and OSSN were 1.5 (CI 0.3 to 2.8) and 6.1 (CI 3.5 to 8.7), respectively. Outcomes for melanoma (mean follow-up 14 years, range 0-34) and OSSN (mean follow-up 4 years, range 0-24) were favourable in 29 cases, with one fatality due to metastatic melanoma. Conclusions In a population-based setting, most conjunctival tumours are benign, and the majority of lesions are melanocytic. While it is important to remain vigilant for malignancies, most conjunctival lesions in a community-based practice are not life-threatening.
InTroduCTIon
A wide variety of benign and malignant tumours occur in the conjunctiva. 1 2 While there have been several large series examining conjunctival lesions in the USA, these reports are primarily from tertiary care centres, making them subject to referral bias. [1] [2] [3] [4] Given that some lesions can be life-threatening, such as conjunctival melanoma, which carries a 25%-30% mortality rate, 5 6 population-based data on the incidence of these tumours are important information for practising physicians.
Current population-based studies reviewing conjunctival melanoma originate mainly from Scandinavia and estimate the annual incidence to be between 0.06 and 0.52 cases per 1 000 000, with an increasing incidence over the past several decades. [5] [6] [7] [8] [9] [10] The incidence of ocular surface squamous neoplasia (OSSN) has ranged from <0.1 cases per 1 000 000 in women in North America to 35 per 1 000 000 in Uganda, [11] [12] [13] [14] [15] [16] and incidence rates are higher with male sex, residence closer to the equator and infection with HIV. 2 16 Although these prior studies have provided valuable information, a US population-based study would add important insights to the literature.
The Rochester Epidemiology Project (REP) captures the medical records of nearly all residents of Olmsted County, Minnesota, and therefore affords an excellent opportunity to determine the incidence of conjunctival tumours in a population-based manner in the USA. In this study, we used the REP database to determine the incidence of benign and malignant conjunctival tumours in Olmsted County patients.
MATerIAls And MeThods
This retrospective study used the REP medical records linkage system, which is a database currently consisting of 148 201 unique residents of Olmsted County, Minnesota, to identify residents with conjunctival tumours. Queries yield only subjects who have authorised medical records review for research. While Mayo Clinic and Olmsted Medical Center provide the majority of medical care in Olmsted County, small independent clinics also participate in the REP, allowing capture of nearly all county residents. 17 18 Private optometry offices are not included. The database is not biased towards patients with health conditions that require more frequent monitoring, and it has excellent agreement for patient status at last contact, date of last contact and date of death compared with manual record abstraction. 19 20 . All patients diagnosed with any type of conjunctival lesion between 1 January 1980 and 31 December 2015 were identified by searching the REP database for 25 unique Hospital International Classification of Diseases Adapted (H-ICDA), 8 unique International Classification of Diseases (ICD)-9 and 24 unique ICD-10 codes (online supplementary eTable 1). Cases were only included if diagnoses were made or confirmed by an ophthalmologist or optometrist, and if they represented benign or malignant tumours. Because our initial search criteria were broad, we reviewed all cases to ensure all tumours were included while excluding degenerative lesions, conjunctivitis, cysts, phylectenules, pingueculae, pterygia, granulomata and depositions. For study inclusion purposes, complexion-associated melanosis was defined as bilateral diffuse pigmentation in a patient of any age with no documentation of change in lesion appearance over time; conjunctival nevus was defined as a single well-circumscribed, cystic lesion or, if non-cystic, required patient age to be 30 years or younger at the time of initial diagnosis; and primary acquired melanosis was defined as single or multiple, unilateral, non-cystic, flat pigmented lesions first documented in white patients older than age 30, or if age 30 or younger required a prior eye exam with no noted lesions. During medical record review, data were collected regarding patient demographics, medical history, ocular findings, clinical impression, treatment and histopathology when available. Tumours were categorised based on the histopathological diagnosis or the clinical diagnosis when histopathology was not available.
Lesions were divided into benign and malignant. While benign melanocytic lesions, such as primary acquired melanosis, can transform into malignant melanoma, these lesions were classified as benign in this study and followed for transformation into melanoma during the study period. Malignant tumours were categorised as melanocytic (malignant melanoma), premalignant/malignant epithelial (OSSN), lymphoma or Langerhans cell histiocytosis. When available, biopsy specimens of malignant lesions and primary acquired melanosis with atypia were retrieved and reviewed by an ophthalmic pathologist (DRS) to confirm and better characterise diagnoses. The age-adjusted and sex-adjusted incidence rate of all conjunctival tumours was calculated, as were the specific incidence rates for melanoma, OSSN and each additional subtype of tumour that had ≥20 cases, by dividing the number of new cases by the number of patients at risk per unit time, given by the population in Olmsted County during the years studied. SAS V.9.4 was used to calculate 95% CIs for incidences. Results are reported as cases per 1 000 000 person-years, and are age-adjusted and sex-adjusted to the 2010 US general population rates. When applicable, the Poisson regression test was used to analyse changes in incidence over time.
resulTs
There were 3369 patients in the REP database diagnosed with a conjunctival lesion between 1 January 1980 and 31 December 2015. Medical record review confirmed the presence of a conjunctival lesion in 919 cases. Of these, we excluded 173 pingueculae, 173 cysts, 50 pterygia, 15 granulomata, 3 phylectenules and 1 case of chronic conjunctivitis. This yielded 504 cases of conjunctival tumour, of which 248 (49%) were in males. Most patients were white (388, 76%), with 50 (10%) Asian, 30 (6%) black, 39 (8%) other races and 2 (<1%) with unknown race. The age-adjusted and sex-adjusted incidence rate of all conjunctival tumours was 125 per 1 000 000 (CI 113.5 to 135.5), and this increased over the course of the study period from 36. In men and women, the adjusted incidence rates of all types of conjunctival tumours were 130.9 (CI 114.3 to 147.4) and 120.1 (CI 105.3 to 134.9), respectively.
benign conjunctival lesions
Most conjunctival tumours were benign (n=474, 94%, table 1). Mean follow-up for all benign tumours was 8±8 years (mean ±SD; range 0-36 years).
benign melanocytic conjunctival lesions
The adjusted incidence of complexion-associated melanosis was 10.8 per 1 000 000 person-years (CI 7.7 to 13.9), with an overall increase in incidence rate over the study period (P<0.001, figure 1 ). The adjusted incidences for men and women, respectively, were 8.3 (CI 4.3 to 12.1) and 13.3 (CI 8.5 to 18.1). None of these lesions showed clinically-appreciable changes over time, with follow-up of 6±8 years (range 0-29 years).
The adjusted incidence rate of conjunctival nevus was 49.7 per 1 000 000 person-years (CI 42.9 to 56.6), with adjusted rates of 54.8 (CI 44.3 to 65.4) and 45.6 (CI 36.6 to 54.6) for men and women, respectively. The incidence rate increased over the study period (P<0.001, figure 1 ). Mean available follow-up was 6±7 years (range 0-35), with 59 patients (28%) having <1 year of Clinical science Benign lymphoid hyperplasia and primary acquired melanosis were classified as benign but can be considered to be premalignant. There were three cases of primary acquired melanosis with mild atypia and none with severe atypia. No benign lesions progressed to malignancy.
follow-up, 58 (28%) having 1-5 years, 44 (21%) having 6-10 years, 19 (9%) having 11-15 years and 30 (14%) having >15 years. No nevus had documented growth or malignant transformation during the available follow-up period. The adjusted incidence rate of primary acquired melanosis was 44.1 per 1 000 000 person-years (CI 37.5 to 50.8) with overall increasing incidence over time (P<0.001, figure 1 ). Adjusted incidence rates for men and women, respectively, were 40.6 (CI 31.4 to 49.9) and 47.0 (CI 37.5 to 56.4). Due to lack of clinical suspicion, only 18 cases (10%) were biopsied. Three biopsies revealed mild atypia (low-risk), with no biopsies showing atypia of greater severity (high risk). Mean available follow-up was 9±8 years (range 0-27), with 32 patients (18%) having <1 year of follow-up, 39 (22%) having 1-5 years, 36 (21%) having 6-10 years, 31 (18%) having 11-15 years and 36 (21%) having >15 years. No patient with primary acquired melanosis progressed to malignant melanoma.
Malignant conjunctival lesions
Malignant lesions accounted for 30 (6%) tumours with most being squamous in origin (table 1). All lesions were primary, and recurrences are indicated in tables 2 and 3 for conjunctival melanoma and OSSN, respectively.
Malignant melanocytic conjunctival lesions
The adjusted incidence rate of conjunctival melanoma in this population was 1.5 per 1 000 000 person-years (CI 0.3 to 2.8).
There were too few cases to ascertain a change in incidence over time, with one case diagnosed in 1982, four in the 1990s and one in 2012 (figure 1). The adjusted incidence rate for men was 2.9 (CI 0.2 to 5.6) and for women was 0.4 (CI 0.0 to 1.1). After mean follow-up of 14 years (range 0-34), five patients (83%) did well, but one patient (17%) required exenteration for recurrence with orbital involvement and later died from metastatic disease (table 2, online supplementary eFigure 1).
Premalignant or malignant conjunctival epithelial lesions
The adjusted incidence rate of OSSN was 6.1 per 1 000 000 person-years (CI 3.5 to 8.7), and the incidence rate appeared to remain stable over time. Adjusted incidence rates for men and women were 12.4 (CI 6.8 to 28.0) and 1.0 (CI 0.0 to 2.4), respectively. After mean follow-up of 4 years (range 0-24), one patient had recurrent disease and no patient developed ocular or orbital invasion or metastases (table 3) .
other malignant conjunctival lesions
There was one case of biopsy-proven Langerhans cell histiocytosis in a 35-year-old patient with 7 months of available follow-up and no systemic Langerhans cell histiocytosis (online supplementary eFigure 2). There were two cases of biopsy-proven lymphoma: one follicular lymphoma in a white patient in their eighth decade with known systemic lymphoma and one diffuse large B cell lymphoma in a white patient in their sixth decade with no known systemic disease and only 1 month of follow-up.
dIsCussIon
This study provides important population-based data regarding the incidence of conjunctival tumours in the USA. The most frequently encountered tumours were benign melanocytic lesions, including nevus (41% of all conjunctival tumours), primary acquired melanosis (34%) and complexion-associated melanosis (9%). Non-pigmented benign conjunctival tumours were less common, accounting for only 9% (48) of all conjunctival tumours and 10% of benign lesions, similar to results from referral centres. 1 2 Benign conjunctival tumours occurred with similar frequency in men and women except for complexion-associated melanosis (more common in women), which might reflect a tendency for women to have more frequent health maintenance visits than men. 21 Tumours (except for complexion-associated melanosis) were most common in white patients, which is likely a reflection of the demographics of Olmsted County.
Regarding primary acquired melanosis, only 18 cases (10%) were biopsied in this series, with 3 cases having mild atypia. The risk of progression to malignant melanoma for primary acquired melanosis has been reported to range from 0% in lesions without atypia to 13% when severe atypia is present. 22 In this series, none of the 174 total cases of primary acquired melanosis progressed to malignant melanoma during the available follow-up period, which was ≥11 years in 39% of cases and ≥6 years in 60% of cases. There was evidence of malignant melanoma arising from primary acquired melanosis with atypia in three of the patients with conjunctival melanoma, but these cases presented as clinically suspicious or changing lesions. No other benign tumours in this series transformed into malignancy after mean follow-up of 8 years, providing reassurance that in a population-based setting most conjunctival lesions, including primary acquired melanosis and nevus without worrisome or changing clinical features, may be observed.
Malignant tumours were most common in middle-aged, white men. As anticipated, malignancies accounted for a much smaller percentage (6%) of all tumours in this population-based study than in series from tertiary referral centres, where >15% and, in some cases, greater than one-third of all lesions harboured malignancy. 1 2 4 Even though we found few malignancies compared with benign lesions, OSSN (4%) was the fourth most frequently occurring tumour in our study. The adjusted incidence rate of conjunctival melanoma in this study (1.5 per 1 000 000, CI 0.3 to 2.8) was similar to adjusted incidence rates in Denmark, which were as high as 2.12 per 1 000 000 (CI 1.23 to 3.65) in the 2000-2009 time period. 7 This was the expected result given the similar demographics and analogous climate of our population compared with those examined previously (table 4) . [5] [6] [7] [8] [9] [10] Numbers were too small to determine if there was any change in incidence over time in our study. However, other studies have reported increasing incidence of conjunctival melanoma, possibly related to better provider reporting and recognition along with increased exposure to ultraviolet radiation. [6] [7] [8] [9] The adjusted incidence rate of OSSN (6.1 per 1 000 000, CI 3.5 to 8.7) was towards the lower end of the reported range (0.1-35 per 1 000 000), [11] [12] [13] [14] [15] [16] which was expected for our North American population with low HIV prevalence (table 4). Although we had small numbers, the incidence rate of OSSN appeared stable over time, in contrast to the increasing incidences in Uganda and Zimbabwe, which may be on the rise secondary to increased exposure to ultraviolet light as well as increased rates of infection with HIV and papillomavirus. While informative, our study is not without limitations. Because the population of Olmsted County is predominantly white, results are most reasonably extrapolated to the semiurban US white population. Population-based data from Olmsted County are similar to data from other US communities, 17 and in 2010, 72% of the total US population was white, 25 supporting this extrapolation. However, the northern latitude of Olmsted County must also be considered as patients living in the southern part of the USA may have different risk factors, such as increased sun exposure, that could alter the incidence and risk of malignant transformation for some conjunctival lesions. Other limitations of this study include its retrospective nature and reliance on provider recognition and clinical documentation for diagnoses. When biopsies were not performed and no photographs were available, clinical descriptions alone were the basis for diagnosis, which was the case for the majority of benign tumours. Finally, the small number of conjunctival malignancies may have influenced our incidence rates, but we reported CIs that aligned with incidence rates in previous studies. It is also possible that our incidence rates for benign lesions might be underestimated if some patients did not seek medical care, were unaware of their condition or were seen at private optometry offices without referral to an ophthalmologist.
This study provides valuable epidemiological data regarding the incidence rates of conjunctival tumours in the USA. The data are directly applicable to general ophthalmologists encountering conjunctival tumours in a population-based primary eye care setting. While most tumours are benign, with low risk for malignant transformation, subspecialty referrals should be made in the setting of changing appearance or worrisome features.
